IPCA Laboratories Has entred into a partnership with biosimular Sciences PR LLC (BSS), US, to Focus on a Next-Generation Monoclonal Antibody Biosimillar Targeting Cancer and Autoimmune Dieseses. IPCA Will Transfer Late-STAGE Development, Clinical Manufacturing, and Commercial Supply to BSS ‘200,000 sq. Ft facility in Puerto Rico.

Lupin Has Received Tentative Approval from the Us Health Regulator for the General Version of Bictegravir, Emtricitaabine, and Tenofovir Alafenamide Tablets used to Treat the HumanDeeciaUS (HIV) (HIV) (HIV) (HIV) (HIV).

Glenmark Specialty Sa, Subsidiary of Glenmark pharmaceuticals, Has signed an exclusive license and collaboration pact with hengrui pharma for development and commercialization of traysuzumab rezetecan, that is aimed at trees of cancer. Under the agreement, glenmark obtains exclusive rights to develop and commercialise traysuzumab rezetcan worldwide, Excluding Mainland China, The Hong Kong Sar, The Macao SAR, TAIWAN REGIN, TAIWAN REGION SAR, TAIWAN SAR Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan, IT Added. Glenmark will pay an upfront payment of $ 18 million. Hengrui is eligible to receive regulatory and commercial millstone payments of up to $ 1.093 billion.

Poly Medicure Has signed an agreement to acquire medistream sa, including citie srl and its subsidiaies in the US and Mexico. The deal is valued at ₹ 324 Crore.

Published on September 25, 2025